Abbott' s Assert-IQ offers the world's longest battery life† for an insertable cardiac monitor The latest addition to Abbott' s portfolio of connected health devices, the Assert-IQ ICM offers ...

The system, which is designed to monitor pressure changes in the heart, is implanted in a patient's pulmonary artery during a minimally invasive procedure. In 2021, Abbott received FDA clearance for ...

Abbott Laboratories landed CE mark for two versions of its Assert-IQ insertable cardiac monitor (ICM), one with a three-year battery life, the other lasting six years. Designed for long-term remote ...

Abbott Laboratories (NYSE: ABT) announced today that it received FDA approval to market its Confirm Rx™ Insertable Cardiac Monitor (ICM), the world’s first and only smartphone compatible ICM ...

The device captures various types of heart data that could be used in AI models for cardiovascular parameters with the aim of ...

Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes Provided by PR Newswire May 15, 2025, 6:05: ...

Abbott is doubling down on the structural heart space as it aims to gain ground in valve replacements following the recent global exit of Boston Scientific.  | CEO Robert Ford said sales of its ...

In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors ...